Regeneron / 再生元

Regeneron / 再生元 appears in 130. 谁才是生物医药行业发展的核心驱动力？兼谈创新药产业链的角色分工 as a BioPharm comparison case. The speakers suggest that Regeneron has meaningful product and development strength but is not necessarily an MNC under the episode’s stricter global-commercialization definition.

Connections

• BioTech To BioPharm Transition - company maturity boundary.
• Global Pharma Commercialization - stricter MNC capability frame.
• Clinical Development Capability - development strength as a partial but not complete differentiator.